메뉴 건너뛰기




Volumn 9, Issue 1, 2016, Pages

Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population

Author keywords

Allele frequencies; CYP2C9; CYP4F2; Pharmacogenetics; VKORC1; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; CYP4F2 PROTEIN, HUMAN; CYTOCHROME P450 2C9; CYTOCHROME P450 FAMILY 4; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN; WARFARIN;

EID: 85003441353     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/s13104-016-2306-x     Document Type: Article
Times cited : (10)

References (29)
  • 1
    • 0037565623 scopus 로고    scopus 로고
    • Pharmacogenetics of oral anticoagulants
    • 1:CAS:528:DC%2BD3sXksVWks78%3D 12724615
    • Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics. 2003;13(5):247-52.
    • (2003) Pharmacogenetics , vol.13 , Issue.5 , pp. 247-252
    • Daly, A.K.1    King, B.P.2
  • 4
    • 31344451857 scopus 로고    scopus 로고
    • Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
    • 1:CAS:528:DC%2BD28Xls1Gksg%3D%3D
    • Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genom. 2006;16(2):101-10.
    • (2006) Pharmacogenet Genom , vol.16 , Issue.2 , pp. 101-110
    • Takahashi, H.1    Wilkinson, G.R.2    Nutescu, E.A.3    Morita, T.4    Ritchie, M.D.5    Scordo, M.G.6    Pengo, V.7    Barban, M.8    Padrini, R.9    Ieiri, I.10
  • 5
    • 33745567198 scopus 로고    scopus 로고
    • Long-term, secondary treatment of deep venous thrombosis: Do we know the appropriate duration of treatment or therapeutic regimen?
    • 15341702
    • Ansell J. Long-term, secondary treatment of deep venous thrombosis: do we know the appropriate duration of treatment or therapeutic regimen? Curr Hematol Rep. 2004;3(5):355-6.
    • (2004) Curr Hematol Rep , vol.3 , Issue.5 , pp. 355-356
    • Ansell, J.1
  • 6
    • 33845500310 scopus 로고    scopus 로고
    • Safety indicators for inpatient and outpatient oral anticoagulant care: [Corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency
    • 1:STN:280:DC%2BD2s%2FisVGhsA%3D%3D 17116128
    • Baglin TP, Cousins D, Keeling DM, Perry DJ, Watson HG. Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol. 2007;136(1):26-9.
    • (2007) Br J Haematol , vol.136 , Issue.1 , pp. 26-29
    • Baglin, T.P.1    Cousins, D.2    Keeling, D.M.3    Perry, D.J.4    Watson, H.G.5
  • 7
    • 0036785249 scopus 로고    scopus 로고
    • Patient-specific factors predictive of warfarin dosage requirements
    • 12243598
    • Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother. 2002;36(10):1512-7.
    • (2002) Ann Pharmacother , vol.36 , Issue.10 , pp. 1512-1517
    • Absher, R.K.1    Moore, M.E.2    Parker, M.H.3
  • 9
    • 77954508907 scopus 로고    scopus 로고
    • CYP4F2 rs2108622: A minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement
    • 1:CAS:528:DC%2BC3cXhtVOmsrfO 20653676 2911553
    • Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol. 2010;70(2):234-40.
    • (2010) Br J Clin Pharmacol , vol.70 , Issue.2 , pp. 234-240
    • Cen, H.J.1    Zeng, W.T.2    Leng, X.Y.3    Huang, M.4    Chen, X.5    Li, J.L.6    Huang, Z.Y.7    Bi, H.C.8    Wang, X.D.9    He, Y.L.10
  • 10
    • 0034872136 scopus 로고    scopus 로고
    • Pharmacogenetics of warfarin elimination and its clinical implications
    • 1:CAS:528:DC%2BD3MXmsl2gsb4%3D 11523725
    • Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001;40(8):587-603.
    • (2001) Clin Pharmacokinet , vol.40 , Issue.8 , pp. 587-603
    • Takahashi, H.1    Echizen, H.2
  • 12
    • 33646205301 scopus 로고    scopus 로고
    • Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals
    • 1:CAS:528:DC%2BD28XlvVenu74%3D 16646575
    • Garcia-Martin E, Martinez C, Ladero JM, Agundez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther. 2006;10(1):29-40.
    • (2006) Mol Diagn Ther , vol.10 , Issue.1 , pp. 29-40
    • Garcia-Martin, E.1    Martinez, C.2    Ladero, J.M.3    Agundez, J.A.4
  • 14
    • 39449086981 scopus 로고    scopus 로고
    • CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study
    • 1:CAS:528:DC%2BD1cXitlGnsbs%3D 17851566
    • Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008;83(3):460-70.
    • (2008) Clin Pharmacol Ther , vol.83 , Issue.3 , pp. 460-470
    • Caraco, Y.1    Blotnick, S.2    Muszkat, M.3
  • 17
    • 77952927473 scopus 로고    scopus 로고
    • Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups
    • 1:CAS:528:DC%2BC3cXmsFSnt7g%3D 20504253 2904527
    • Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics. 2010;11(6):781-91.
    • (2010) Pharmacogenomics , vol.11 , Issue.6 , pp. 781-791
    • Scott, S.A.1    Khasawneh, R.2    Peter, I.3    Kornreich, R.4    Desnick, R.J.5
  • 18
    • 23044440450 scopus 로고    scopus 로고
    • The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen
    • 1:CAS:528:DC%2BD2MXhtVKqt7%2FL 15947090
    • Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329-33.
    • (2005) Blood , vol.106 , Issue.7 , pp. 2329-2333
    • Sconce, E.A.1    Khan, T.I.2    Wynne, H.A.3    Avery, P.4    Monkhouse, L.5    King, B.P.6    Wood, P.7    Kesteven, P.8    Daly, A.K.9    Kamali, F.10
  • 20
    • 34248525060 scopus 로고    scopus 로고
    • HIV-infected African Americans are willing to participate in HIV treatment trials
    • 17351837 1824784
    • Garber M, Hanusa BH, Switzer GE, Mellors J, Arnold RM. HIV-infected African Americans are willing to participate in HIV treatment trials. J Gen Intern Med. 2007;22(1):17-42.
    • (2007) J Gen Intern Med , vol.22 , Issue.1 , pp. 17-42
    • Garber, M.1    Hanusa, B.H.2    Switzer, G.E.3    Mellors, J.4    Arnold, R.M.5
  • 21
    • 34547658151 scopus 로고    scopus 로고
    • Effect of patient-specific factors on weekly warfarin dose
    • 1:CAS:528:DC%2BD2sXps1CqtrY%3D 18488070 2386352
    • Whitley HP, Fermo JD, Chumney EC, Brzezinski WA. Effect of patient-specific factors on weekly warfarin dose. Ther Clin Risk Manag. 2007;3(3):499-504.
    • (2007) Ther Clin Risk Manag , vol.3 , Issue.3 , pp. 499-504
    • Whitley, H.P.1    Fermo, J.D.2    Chumney, E.C.3    Brzezinski, W.A.4
  • 22
    • 0036434235 scopus 로고    scopus 로고
    • Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population
    • 1:CAS:528:DC%2BD38Xps1Olsbs%3D 12445031 1874480
    • Burian M, Grosch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol. 2002;54(5):518-21.
    • (2002) Br J Clin Pharmacol , vol.54 , Issue.5 , pp. 518-521
    • Burian, M.1    Grosch, S.2    Tegeder, I.3    Geisslinger, G.4
  • 23
    • 64149111606 scopus 로고    scopus 로고
    • Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and Vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2
    • 1:CAS:528:DC%2BD1MXktVWqsbg%3D 19181737
    • Aomori T, Yamamoto K, Oguchi-Katayama A, Kawai Y, Ishidao T, Mitani Y, Kogo Y, Lezhava A, Fujita Y, Obayashi K, et al. Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2. Clin Chem. 2009;55(4):804-12.
    • (2009) Clin Chem , vol.55 , Issue.4 , pp. 804-812
    • Aomori, T.1    Yamamoto, K.2    Oguchi-Katayama, A.3    Kawai, Y.4    Ishidao, T.5    Mitani, Y.6    Kogo, Y.7    Lezhava, A.8    Fujita, Y.9    Obayashi, K.10
  • 24
    • 73149102765 scopus 로고    scopus 로고
    • Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
    • 19954515 3224726
    • Kudzi W, Dodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet. 2009;10:124.
    • (2009) BMC Med Genet , vol.10 , pp. 124
    • Kudzi, W.1    Dodoo, A.N.2    Mills, J.J.3
  • 25
    • 0344512432 scopus 로고    scopus 로고
    • Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations
    • 1:CAS:528:DC%2BD2cXivFSmsA%3D%3D 14616425 1884305
    • Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol. 2003;56(6):653-7.
    • (2003) Br J Clin Pharmacol , vol.56 , Issue.6 , pp. 653-657
    • Allabi, A.C.1    Gala, J.L.2    Desager, J.P.3    Heusterspreute, M.4    Horsmans, Y.5
  • 26
    • 79959411039 scopus 로고    scopus 로고
    • Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans and Brazilians
    • 1:CAS:528:DC%2BC3MXnvVakurw%3D 21692610
    • Vargens DD, Damasceno A, Petzl-Erler ML, Suarez-Kurtz G. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans and Brazilians. Pharmacogenomics. 2011;12(6):769-72.
    • (2011) Pharmacogenomics , vol.12 , Issue.6 , pp. 769-772
    • Vargens, D.D.1    Damasceno, A.2    Petzl-Erler, M.L.3    Suarez-Kurtz, G.4
  • 27
    • 70649111382 scopus 로고    scopus 로고
    • CYP2C9∗8 is prevalent among African-Americans: Implications for pharmacogenetic dosing
    • 1:CAS:528:DC%2BD1MXpslOmu7g%3D 19663669 2737687
    • Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9∗8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics. 2009;10(8):1243-55.
    • (2009) Pharmacogenomics , vol.10 , Issue.8 , pp. 1243-1255
    • Scott, S.A.1    Jaremko, M.2    Lubitz, S.A.3    Kornreich, R.4    Halperin, J.L.5    Desnick, R.J.6
  • 28
    • 40749123052 scopus 로고    scopus 로고
    • Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations
    • 1:CAS:528:DC%2BD1cXit1Sisrk%3D 18252229 2427171
    • Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet. 2008;82(2):495-500.
    • (2008) Am J Hum Genet , vol.82 , Issue.2 , pp. 495-500
    • Scott, S.A.1    Edelmann, L.2    Kornreich, R.3    Desnick, R.J.4
  • 29
    • 62349134303 scopus 로고    scopus 로고
    • Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: A prospective study in Chinese patients
    • 1:CAS:528:DC%2BD1MXjsVWqsbk%3D
    • Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genom. 2009;19(3):226-34.
    • (2009) Pharmacogenet Genom , vol.19 , Issue.3 , pp. 226-234
    • Huang, S.W.1    Chen, H.S.2    Wang, X.Q.3    Huang, L.4    Xu, D.L.5    Hu, X.J.6    Huang, Z.H.7    He, Y.8    Chen, K.M.9    Xiang, D.K.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.